

Rina Hui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7514355/publications.pdf>

Version: 2024-02-01

66
papers

23,830
citations

201575

27
h-index

138417

58
g-index

66
all docs

66
docs citations

66
times ranked

21973
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1823-1833.	13.9	7,847
2	Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 2018-2028.	13.9	5,183
3	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 2078-2092.	13.9	4,701
4	Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. <i>Journal of Clinical Oncology</i> , 2019, 37, 537-546.	0.8	1,144
5	Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2518-2527.	0.8	811
6	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1505-1517.	0.8	710
7	Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \geq 50%. <i>Journal of Clinical Oncology</i> , 2021, 39, 2339-2349.	0.8	468
8	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1301-1311.	0.8	445
9	Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 288-293.	0.5	328
10	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 371-382.	5.1	327
11	Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1600-1609.	5.1	282
12	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. <i>Clinical Breast Cancer</i> , 2021, 21, 80-91.e7.	1.1	140
13	Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 347-357.	5.2	137
14	Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1670-1680.	5.1	125
15	Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 387-397.	5.1	119
16	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1008-1008.	0.8	99
17	Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) \pm anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. , 2022, 10, e003776.		79
18	Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study. <i>PLoS ONE</i> , 2017, 12, e0175544.	1.1	64

#	ARTICLE	IF	CITATIONS
19	Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study. <i>Clinical Cancer Research</i> , 2016, 22, 3164-3171.	3.2	60
20	Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3012-3012.	0.8	58
21	Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9000-9000.	0.8	43
22	KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9013-9013.	0.8	42
23	Lucitanib for the Treatment of HR+/HER2 ⁺ Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , 2020, 26, 354-363.	3.2	40
24	Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.. <i>Journal of Clinical Oncology</i> , 2022, 40, 503-503.	0.8	38
25	Physical Activity for Symptom Management in Women With Metastatic Breast Cancer: A Randomized Feasibility Trial on Physical Activity and Breast Metastases. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 929-939.	0.6	35
26	Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?. , 2021, 9, e002248.		35
27	Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1 ⁺ Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100205.	0.6	32
28	Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8007-8007.	0.8	32
29	Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9026-9026.	0.8	31
30	Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC). <i>Lung Cancer</i> , 2021, 151, 30-38.	0.9	30
31	Three-year overall survival update from the PACIFIC trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8526-8526.	0.8	29
32	Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation.. <i>Journal of Clinical Oncology</i> , 2013, 31, 543-543.	0.8	26
33	Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PACIFIC). <i>Clinical Lung Cancer</i> , 2021, 22, 549-561.	1.1	25
34	Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8020-8020.	0.8	25
35	Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2 ⁻) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 568-568.	0.8	25
36	Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. <i>Lung Cancer</i> , 2021, 155, 28-33.	0.9	18

#	ARTICLE	IF	CITATIONS
37	KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab.. Journal of Clinical Oncology, 2017, 35, 9011-9011.	0.8	18
38	Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.. Journal of Clinical Oncology, 2020, 38, 9521-9521.	0.8	17
39	Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials. JNCI Cancer Spectrum, 2021, 5, pKab012.	1.4	16
40	Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2020, 38, 9582-9582.	0.8	16
41	Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) + pemetrexed (pem) + platinum (plt) for metastatic NSCLC.. Journal of Clinical Oncology, 2018, 36, 9021-9021.	0.8	15
42	Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001.. Journal of Clinical Oncology, 2015, 33, 8026-8026.	0.8	12
43	CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 3-14.	0.7	11
44	4-year overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.. Journal of Clinical Oncology, 2018, 36, 9030-9030.	0.8	11
45	Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?. Breast, 2019, 46, 52-57.	0.9	9
46	Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001.. Journal of Clinical Oncology, 2019, 37, LBA9015-LBA9015.	0.8	9
47	Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non-small cell lung cancer (NSCLC): LEAP-006.. Journal of Clinical Oncology, 2019, 37, TPS9118-TPS9118.	0.8	7
48	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. Lung Cancer, 2022, 166, 84-93.	0.9	7
49	Epidermal growth factor receptor inhibitor-induced papulopustular eruption successfully treated with low-dose oral dapsone. Australasian Journal of Dermatology, 2018, 59, e219-e220.	0.4	6
50	Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010.. Journal of Clinical Oncology, 2017, 35, 77-77.	0.8	6
51	Neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant early-stage triple-negative breast cancer (TNBC): A single-arm phase 2 trial.. Journal of Clinical Oncology, 2022, 40, 602-602.	0.8	6
52	Patterns of care for stage III non-small cell lung cancer in Australia. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 93-100.	0.7	5
53	Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses. Cancer Research, 2022, 82, GS1-01-GS1-01.	0.4	5
54	ECHO-306/KEYNOTE-715: A phase 3 study of first-line epacadostat plus pembrolizumab with or without platinum-based chemotherapy vs pembrolizumab plus platinum-based chemotherapy plus placebo for metastatic non-small cell lung cancer (mNSCLC).. Journal of Clinical Oncology, 2018, 36, TPS9104-TPS9104.	0.8	4

#	ARTICLE	IF	CITATIONS
55	387â€¦A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies. , 2020, , .		4
56	Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio. Breast, 2020, 54, 229-234.	0.9	3
57	First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC.. Journal of Clinical Oncology, 2019, 37, 9054-9054.	0.8	3
58	Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer. Future Oncology, 2021, 17, 1165-1184.	1.1	2
59	Duration of extended adjuvant therapy with neratinib in early-stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial.. Journal of Clinical Oncology, 2018, 36, 524-524.	0.8	2
60	Rate of cancer progression as a predictive marker of efficacy of immunotherapy; an analysis in metastatic non-small-cell lung cancer. Immunotherapy, 2019, 11, 657-665.	1.0	1
61	Non-pneumonitis immune-mediated adverse events (imAEs) with durvalumab in patients with unresectable stage III NSCLC (PACIFIC).. Journal of Clinical Oncology, 2020, 38, 9048-9048.	0.8	1
62	Abstract OT2-01-03: Trial in progress: Phase 2 study of intratumoral plasmid interleukin-12 (tavokinogene telseplasmid; TAVOâ„¢) plus electroporation in combination with pembrolizumab with or without chemotherapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (KEYNOTE-890/OMS-1141). Cancer Research, 2022, 82, OT2-01-03-OT2-01-03.	0.4	1
63	<i>CYP2D6</i> genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen.. Journal of Clinical Oncology, 2012, 30, 550-550.	0.8	0
64	Should culture affect practice? Prognostic discussions with immigrants.. Journal of Clinical Oncology, 2013, 31, 6556-6556.	0.8	0
65	Physical activity and fitness in women with metastatic breast cancer.. Journal of Clinical Oncology, 2013, 31, 136-136.	0.8	0
66	364â€¦.KRAS mutations in patients with nonsquamous nonâ€œsmall-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status. , 2021, 9, A391-A391.		0